Abu Dhabi [UAE], Department of Health – Abu Dhabi (DoH) has signed a Memorandum of Understanding (MoU) with Illumina, the global leader in DNA sequencing and array-based technologies, to advance precision medicine and clinical genomics research. Have signed.
This partnership aims to develop the expertise, infrastructure and skilled workforce needed to integrate genomics into clinical practice and translational research both locally and internationally.
The MoU was signed in the presence of Mansour Ibrahim Al Mansouri, Chairman of the DoH, and Jacob Thyssen, Chief Executive Officer of Illumina, during the BIO 2024 international conference in the United States.
It was signed by Dr. Asma Ibrahim Al Mannai, Executive Director of the Research and Innovation Center at DoH, and Steve Bernard, Chief Technology Officer of Illumina.
Under the leadership of DoH, a high-profile Abu Dhabi delegation led by Al Mansouri attended the event to showcase the emirate's partnership opportunities and explore collaboration with leading organizations in research and development (R&D), manufacturing and innovation. Toured the United States between May 29 and June 5.Genomics has the potential to transform the future health of humanity. From disease prediction to diagnosis, drug discovery to personalized treatments, genomics cannot be understated as a revolutionary force for global well-being.
Leveraging Abu Dhabi's wealth of genomic data, DoH and Illumina seek to accelerate innovations in genomics and precision medicine, focusing on emerging genomic applications. This includes genomic and multi-omics advanced analysis and interpretation to drive the development of new breakthrough diagnostics for precision medicine and benefit patients locally and globally.
Dr. Al Mannai said genomics research, development and practical application of its insights and treatments are central pillars of the DoH strategy to establish Abu Dhabi as a global life sciences hub.“Through this new partnership with Illumina, we aim to deliver breakthroughs in personalized, predictive and preventive programs tailored to an individual's genetic makeup. It is only through borderless collaboration in pursuit of a common goal, that we “Can deliver truly translational research and skill our workforce with the tools that will future-proof global public health and enable a healthy future for all,” he added.
Barnard said, “The MOU signed today is an important milestone in accelerating genomic innovation in the UAE through access to the latest sequencing technology, advanced genomic analysis solutions and workforce training initiatives."
This partnership aims to develop the expertise, infrastructure and skilled workforce needed to integrate genomics into clinical practice and translational research both locally and internationally.
The MoU was signed in the presence of Mansour Ibrahim Al Mansouri, Chairman of the DoH, and Jacob Thyssen, Chief Executive Officer of Illumina, during the BIO 2024 international conference in the United States.
It was signed by Dr. Asma Ibrahim Al Mannai, Executive Director of the Research and Innovation Center at DoH, and Steve Bernard, Chief Technology Officer of Illumina.
Under the leadership of DoH, a high-profile Abu Dhabi delegation led by Al Mansouri attended the event to showcase the emirate's partnership opportunities and explore collaboration with leading organizations in research and development (R&D), manufacturing and innovation. Toured the United States between May 29 and June 5.Genomics has the potential to transform the future health of humanity. From disease prediction to diagnosis, drug discovery to personalized treatments, genomics cannot be understated as a revolutionary force for global well-being.
Leveraging Abu Dhabi's wealth of genomic data, DoH and Illumina seek to accelerate innovations in genomics and precision medicine, focusing on emerging genomic applications. This includes genomic and multi-omics advanced analysis and interpretation to drive the development of new breakthrough diagnostics for precision medicine and benefit patients locally and globally.
Dr. Al Mannai said genomics research, development and practical application of its insights and treatments are central pillars of the DoH strategy to establish Abu Dhabi as a global life sciences hub.“Through this new partnership with Illumina, we aim to deliver breakthroughs in personalized, predictive and preventive programs tailored to an individual's genetic makeup. It is only through borderless collaboration in pursuit of a common goal, that we “Can deliver truly translational research and skill our workforce with the tools that will future-proof global public health and enable a healthy future for all,” he added.
Barnard said, “The MOU signed today is an important milestone in accelerating genomic innovation in the UAE through access to the latest sequencing technology, advanced genomic analysis solutions and workforce training initiatives."
